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Abstract
Background: CD8
+ effector cells often have an antitumor function in patients with cancer. However, CD8
+Foxp3
+
regulatory T cells (Tcregs) and interleukin (IL)-17-producing CD8
+ T cells (Tc17 cells) also derive from the CD8
+ T
cell lineage. Their role in the antitumor response remains largely unknown. In the present study, we aimed to
investigate the distribution, characterization, and generation of CD8
+ Tcregs and Tc17 cells in NPC patients.
Methods: Peripheral blood and tumor biopsy tissues from 21 newly diagnosed patients with nasopharyngeal
carcinoma (NPC) were collected, along with peripheral blood from 21 healthy donors. The biological characteristics
of Tcregs and Tc17 cells from blood and tumor tissues were examined by intracellular staining, tetramer staining
and fluorescence-activated cell sorting (FACS) analysis. The suppressive function of Tcregs was investigated using a
proliferation assay that involved co-culture of sorted CD8
+CD25
+ T cells with naïve CD4
+ T cells in vitro.
Results: We observed an increased prevalence of Tcregs and Tc17 cells among tumor-infiltrating lymphocytes
(TILs) and different distribution among peripheral blood mononuclear cells (PBMCs) in NPC patients. Cytokine
profiles showed that the Tcregs expressed a high level of IL-10 and low level of transforming growth factor b,
whereas Tc17 cells expressed a high level of tumor necrosis factor a. Interestingly, both subsets expressed a high
level of interferon g in TILs, and the Tcregs suppressed naïve CD4
+ T cell proliferation by a cell contact-dependent
mechanism in vitro. Moreover, we demonstrated the existence of Epstein-Barr virus latent membrane protein (LMP)
1 and LMP2 antigen-specific Tcregs in NPC.
Conclusions: Our data provide new insights into the composition and function of CD8
+ T-cell subsets in NPC,
which may have an important influence on NPC immunotherapy.
Keywords: Nasopharyngeal carcinoma, Tumor-infiltrating lymphocytes, CD8
+ regulatory T cells (Tcreg), IL-17-produ-
cing CD8
+ T cells (Tc17)
Background
Undifferentiated nasopharyngeal carcinoma (NPC) is
associated with Epstein-Barr virus (EBV) infection,
which has a high incidence in Southern China and
Southeast Asia. Conventional therapy is often ineffective
for NPC patients with late-stage disease [1,2]. Recently,
immunotherapy has become a promising therapeutic
option for various types of cancer with high
immunogenicity, including NPC [3-5]. The success of
EBV-specific cytotoxic T lymphocyte (CTL) treatment
has been reported in NPC. However, it has been difficult
to obtain consistent results or stable clinical efficacy
[6-8]. One possibility is that immune-suppressive envir-
onments may be created in patients with NPC [9-11].
Thus, a better understanding of the immune status of
NPC patients, including the distribution of specific lym-
phocyte subsets and their functions, is crucial in devel-
oping more effective immunotherapy strategies.
CD8
+ T cells that express high levels of the transcrip-
tion factors Eomes and T-bet are usually destined to
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feron (IFN) g, granzyme B and perforin, however, CD8
+
cells may also give rise to a regulatory lineage (Tcreg).
The CD4
+Foxp3
+ regulatory T cells (Tregs), which have
been recognized as a suppressor of antitumor immunity
because of its natural suppressive effect on the prolifera-
tion and IL-2 secretion of naïve and effector T cells
[12,13], but the distribution, generation, characteristics,
and function of Tcregs in cancer remain poorly under-
stood, as does their pathogenic antigen specificity.
Furthermore, interleukin (IL)-17-producing CD8
+ T cells
(Tc17 cells) have been identified in mice and humans,
and their enrichment inside solid tumors has been
reported [14]. However, the generation and function of
Tc17 cells in cancer remain largely uncharacterized.
In this study, we aimed to investigate the distribution,
characterization, and generation of CD8
+ Tcregs and
Tc17 cells in NPC patients. We observed an increase of
Tcregs and decrease of Tc17 cells from peripheral blood
mononuclear cells (PBMCs) and an accumulation of
Tcregs and Tc17 cells in tumor tissues from 21 NPC
patients. The Tcreg subset expressed CC chemokine
receptor 6 (CCR6), cytotoxic T lymphocyte antigen 4
(CTLA4), and glucocorticoid-induced tumor necrosis
factor (TNF)-related (GITR) proteins at high levels,
resulting in a Treg-like phenotype. The Tc17 cells
expressed high levels of CCR6 and low levels of CTLA4
and GITR protein, and they contained a high proportion
of cells secreting TNFa,w h i c hi saT h 1c y t o k i n e .M o r e -
over, the Tcregs from the tumor-infiltrating lymphocytes
(TILs) secreted high levels of IL-10 and IFNg but low
levels of IL-2, IL-4, TNFa, and IL-17, resulting in a Tr1-
like cytokine profile; Tcregs from PBMCs, in contrast,
secreted high levels of IL-10 and low levels of transform-
ing growth factor b (TGFb), IL-2, IFNg,T N F a,a n dI L -
17. In addition, there was a significantly higher percen-
tage of IFNg-secreting cells among the Tc17 cells from
the TILs than among those from the PBMCs, and this
was true of cells from both NPC patients and healthy
donors. Furthermore, the Tcregs from NPC patients pos-
sessed a suppressive function to the proliferation of CD4
+ naive T cells, which was mainly mediated by a cell-to-
cell contact-dependent mechanism. IFNg failed to impair
the suppressive function of Tcregs in vitro. Collectively,
these data suggest that, in addition to CD8
+ cytolytic
effector cells, Tcregs and Tc17 cells with diverse func-
tions are present in NPC patients. Additionally, this is
the first demonstration of the existence of EBV antigen-
induced Tcregs in patients with NPC.
Materials and methods
Samples
Tumor biopsy tissues and blood samples were col-
lected from 21 newly diagnosed patients with NPC in
Sun Yat-Sen University Cancer Center between 2009
and 2010. The tissue samples were cut into pieces. In
addition to pathological diagnosis, one portion was
used to generate and expand TILs, and another por-
tion was used for fluorescence-activated sorting
(FACS) analysis. Prior to FACS analysis, cells were
briefly cultured in low dose IL-2 (20 IU/ml) RPMI
1640 complete medium to obtain a sufficient number
of lymphocytes. PBMCs were isolated from the blood
samples of 21 patients with NPC and 21 age-matched
healthy donors; the samples had been frozen for FACS
analysis. This study was conducted in accordance with
the Helsinki Declaration, with written informed con-
sent provided by the patients and with approval from
the Research Ethics Committee of the Sun Yat-Sen
University Cancer Center. Written consent was also
obtained from all healthy donors before their
participation.
Generation of TILs and FACS analysis
Bulk TILs were isolated from the NPC biopsy specimens
by mincing the tissue into small pieces and digesting
with collagenase type IV. Cells were then cultured in
RPMI 1640 medium that contained 10% human AB
serum supplemented with L-glutamine, 2-mercaptoetha-
nol, and recombinant human IL-2 (300 IU/ml) so as to
generate T cells, as described previously [15].
The expression of markers on T cells was investigated
by FACS analysis after surface or intracellular staining
with specific antibodies that were conjugated to different
fluorescent dyes (eBioscience, San Diego, CA, USA).
Intracellular staining for IL-17 and other cytokines was
performed on T cells stimulated by phorbol12-myris-
tate13-acetate (PMA) and ionomycin for 4 h in the pre-
sence of brefeldin A (10 μg/ml, Sigma-Aldrich).
Intracellular cytokines and Foxp3 were detected using a
fixation and permeabilization protocol and buffers that
were purchased from eBioscience.
The proportion of T cells that were specific for
HLA-A2-restricted epitopes in LMP1 and LMP2 were
analyzed by staining with HLA-A2 tetramers. The tet-
ramers were assembled with synthetic peptides that
originated from LMP1 (YLQQNWWTL) and LMP2
(LLWTLVVLL and GLGTLGAAI) (Guangzhou Taimo
Corporation, Guangzhou, China). Aliquots of 0.5-1 ×
10
6 cells were incubated at 4°C for 30 min in PBS
that contained 1% fetal calf serum and 1 μg/ml phy-
coerythrin (PE)-labeled tetrameric complex. The sam-
ples were stained with anti-CD8-FITC and anti-
Foxp3-APC antibodies and were then fixed in 0.5%
paraformaldehyde for 20 min. For each sample, 10
5
cells were analyzed using an FC500 flow cytometer
and CXP analysis software (Beckman Coulter, Inc.,
Fullerton, CA, USA).
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+CD25
+ Tcregs and
suppression assay
CD8
+CD25
+ Treg cells from PBMCs or TILs were
stained with anti-CD8 and anti-CD25 antibodies and
were sorted by FACS (MoFlo XDP Cell Sorter; Beckman
Coulter, Inc.). Proliferation assays were performed as
described previously [16]. In brief, 10
5 CD4
+ naïve T
cells or CD8
+ effector T cells were labeled with 5- or 6-
(N-Succinimidyloxycarbonyl)-3’,6 ’-O, O’-diacetylfluores-
cein (CSFE, Invitrogen) and co-cultured with CD8
+
Tregs at the indicated ratios. Cells were co-cultured for
5 days in 96-well round-bottom plates coated with
human anti-CD3 (1 μg/ml), with or without the pre-
sence of anti-IL-10 or anti-IFNg antibodies. The prolif-
eration of CSFE-labeled CD4
+ naïve T cells was
detected by FACS analysis. Transwell experiments were
performed in 24-well plates using inserts with a pore
size of 0.4 μm (Corning Gilbert Inc, Arizona, USA).
Statistical analysis
Numerical data were expressed as means ± standard
error. Statistical differences between the means for the
different groups were evaluated with SSPS 13.0 software
using a one-way analysis of variance with the level of
significance at P < 0.05.
Results
Distribution and proportion of CD8
+ Tcregs and Tc17
cells in patients with NPC
Our previous study showed that the density of CD8
+
TILs is not a favorable prognostic factor for NPC patients
[17]. Here, we continued to investigate the characteristics
of CD8
+ T cells from the PBMCs and TILs of individual
NPC patients (Table 1), and we included matched
healthy individuals as controls. We examined the percen-
tage of CD8
+Foxp3
+ Tcregs from PBMCs and freshly iso-
lated TILs of NPC patients by analyzing the expression of
CD8 and Foxp3 (Figure 1). The proportion of CD8
+Foxp3
+ Tcregs was increased significantly in PBMCs
from NPC patients (mean = 3.13 ± 5.04%, n =2 1 )a s
compared with healthy donors (mean = 0.8 ± 1.03%, n =
21; P < 0.05, Figure 2A), and the proportion of Tcregs in
TILs (mean = 2.67 ± 3.36%, n = 21) was similar to that in
PBMCs from paired NPC patients (Figure 2B). In addi-
tion to the Tcregs, the CD8
+ T cells contained a popula-
tion of Tc17 cells, and we found that the percentage of
Tc17 cells in PBMCs from NPC patients (mean = 0.29 ±
0.31%, n = 21) was significantly lower than that in
PBMCs from healthy donors (mean = 1.04 ± 0.72%, n =
21) or TILs from the paired NPC patients (mean = 0.96 ±
1.12%, n = 21) (P < 0.005, Figure 2C, D)
Table 1 Sample information
No. Gender Age (yr) Histological type
a WHO classification
b Clinical stage
NPC1 F 52 III T3N1M0 III
NPC2 M 29 III T2N2M0 III
NPC3 M 53 III T3N0M0 III
NPC4 M 45 III T4N2M0 IVA
NPC5 M 46 III T4N1M0 IVA
NPC6 M 47 III T2N0M0 II
NPC7 M 63 III T4N2M0 IVA
NPC8 M 36 III T3N1M0 III
NPC9 M 44 III T3N1M0 III
NPC10 F 29 III T2N2M0 III
NPC11 M 38 III T2N2M0 III
NPC12 F 31 III T3N2M0 III
NPC13 M 39 III T3N2M0 III
NPC14 F 25 III T3N1M0 III
NPC15 M 38 III T3N2M0 III
NPC16 M 34 III T3N1M0 III
NPC17 M 38 III T3N2M0 III
NPC18 M 42 III T3N1M0 III
NPC19 M 30 III T3N2M1 IVA
NPC20 M 54 III T2N1M0 II
NPC21 M 56 III T2N2M0 IVA
aHistological type: I = differentiated keratinizing squamous cell carcinoma; II = differentiated nonkeratinizing carcinoma; III = undifferentiated carcinoma.
bTNM
stage according to WHO UICC-AJCC 1997 standards (International Union Against Cancer/American Joint Committee on Cancer)
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Figure 1 Representative FACS dot plot for CD8 and Foxp3 staining or CD8 and IL-17 staining of PBMCs from healthy donors or
PBMCs and TILs from one paired NPC patient.
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Figure 2 Distribution of Tcregs and Tc17 cells in PBMCs and TILs from paired NPC patients. The proportion of Tcregs (A, B) and Tc17 cells
(C, D) in total CD8
+ T cells from PBMCs and freshly isolated TILs of paired NPC patients (n = 21) and healthy donors (HD, n = 21). Subsets were
identified by intracellular staining of Foxp3 and IL-17 after PMA/ionomycin stimulation in vitro. Cumulative data show a significant increase in the
number of Tcregs in PBMCs and TILs of NPC patients as compared with PBMCs of healthy donors and a significant decrease in Tc17 cells from
PBMCs of NPC patients as compared with TILs from NPC patients and PBMCs from healthy donors.
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+ Tcreg and
Tc17 subsets in NPC
To characterize the subsets of Tcregs and Tc17 cells, we
analyzed the phenotypic features of these cells (Figure
3A). The Tcregs in both PBMCs and TILs expressed
CD45RO and CD45RA, indicating that this subset con-
tained memory Tcregs and naïve Tcregs. The Tc17 cells
from PBMCs also expressed CD45RO and CD45RA;
however, the Tc17 cells from TILs were positive for
CD45RO protein but negative for CD45RA. This indi-
cates that Tc17 cells contained memory and naïve Tc17
cells in PBMCs but only memory Tc17 cells in TILs.
Moreover, the Tcregs and Tc17 cells in PBMCs showed
high levels of CCR6 and CCR7, whereas these subsets in
TILs expressed high levels of CCR6 and low levels of
CCR7. The Tcregs also expressed specific molecular
markers of CD4
+ Tregs, including CTLA4 and GITR,
whereas the Tc17 cells expressed moderate levels of
CTLA4 but were negative for GITR protein.
N e x t ,w ee v a l u a t e dt h ec y t o k i n ee x p r e s s i o np r o f i l eo f
Tcregs and Tc17 cells in PBMCs and TILs from NPC
patients after stimulation with PMA/ionomycin in
vitro.D a t aw e r ea c q u i r e df o rP B M C sa n dT I L s ,a n d
the assay was repeated 5 times with different donors,
a ss h o w ni nF i g u r e3 Ba n d3 C .T c r e g si nP B M C sf r o m
NPC patients and healthy donors showed high expres-
sion of IL-10 and low expression of TGFb,I L - 2 ,I F N g,
TNFa, and IL-17. The Tcreg subset in TILs contained
as i g n i f i c a n t l yh i g h e rp r o p o r t i o no fI F N g-secreting cells
than Tcregs from PBMCs of NPC patients and healthy
donors (P =0 . 0 0 1 ) .T h ec y t o k i n ee x p r e s s i o np r o f i l eo f
Tcregs from TILs was IFNg
highIL-10
highTGFb
lowIL-2
low-
TNFa
lowIL-17
low, which indicated that Tcregs dis-
played a Tr1-like cytokine expression profile in the
tumor microenvironment. The Tc17 cells also con-
tained a high proportion of TNFa-secreting cells and
some IL-10- and IL-2-secreting cells. Additionally, the
Tc17 cells from TILs contained a much higher
C
y
t
o
k
i
n
e
 
s
e
c
r
e
t
i
n
g
 
c
e
l
l
s
 
(
%
)
 
C
y
t
o
k
i
n
e
 
s
e
c
r
e
t
i
n
g
 
c
e
l
l
s
 
(
%
)
 
Gated on CD8+IL17+ T cells   C 
HD PBMC 
NPC PBMC
NPC TIL 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
IL2 IFNJ TNFD IL-10  TGFE
* 
HD PBMC 
NPC PBMC 
NPC TIL 
Gated on CD8+Foxp3+ T cells  B 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
IL2 IFNJ TNFD IL-17 IL-10 TGFE
* 
Figure 3 Characterization of Tcregs and Tc17 cells in NPC. (A) Expression of phenotypic markers, including CD45RO, CD45RA, CCR6, CCR7,
CTLA4, and GITR, on Tcregs and Tc17 cells from PBMCs and TILs of one representative NPC patient. (B and C) Cytokine profiles of Tcregs (B) and
Tc17 cells (C). Tcregs expressed high levels of IL-10 but low levels of IL-2, TNFa, IL-17, and IFNg, except Tcregs from TILs, which expressed
significantly higher levels of IFNg compared with NPC PBMCs. Tc17 cells expressed high levels of TNFa, an intermediate level of IL-10, and low
levels of IL-2 and IFNg, except for cells from TILs, which also expressed significantly higher levels of IFNg compared with NPC PBMCs. Data are
from five patients with NPC and five healthy donors. *P < 0.005.
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Page 5 of 10percentage of IFNg-secreting cells than those from
PBMCs of NPC patients or healthy donors (P <
0.0001).
We investigated the suppressive function of Tcregs on
naïve T cells in vitro by sorting CD8
+CD25
+ Tc e l l s
from peripheral PBMCs and TILs from NPC patients.
The sorted CD8
+CD25
+ T cells expressed a higher level
of Foxp3 protein than the unsorted cells (Figure 4A),
and they suppressed the proliferation of naïve CD4
+ T
cells and CD8
+ effector T cells when the cells were co-
cultured at different ratios in vitro,a sd oC D 4
+ Tregs
(Figures 4B and Additional file 1). This suppression
A 
B 
Naive CD4+ T 
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Figure 4 Suppressive function of CD8
+ Tregs in vitro. (A) CD8
+ Tregs were isolated from TILs of NPC patients by sorting the CD8
+CD25
+ T
cells by flow cytometry. Representative dot plots for CD8, CD25, and Foxp3 before and after sorting are shown. (B) The suppressive activity of
CD8
+ Tregs on naïve CD4
+ T cells in vitro was detected by proliferation of CSFE-labeled naïve CD4
+ T cells. CSFE-labeled naïve CD4
+ T cells were
cultured alone or with CD8
+ Tregs at different ratios, in the outer and inner chamber of a transwell system, or in the presence of anti-IL-10 or
anti-IFNg antibodies in low IL-2 medium in 96-well or 24-well plates coated with OKT3 for 5 days. Representative results from one of five
experiments are shown.
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slightly inhibited by anti-IL-10 antibody but not by anti-
IFNg antibody (Figure 4B). This indicates that suppres-
sion by Tcregs in vitro was mainly mediated by cell-to-
cell contact. Moreover, IFNg also did not influence the
suppressive function of Tcregs in vitro.
EBV-antigen-specific CD8
+Foxp3
+ Tregs were identified in
NPC
NPC tumor cells can present EBV latent type II anti-
gens, including LMP1, LMP2, EBNA1, and BARF0.
EBV-antigen-specific CD8
+ effector cells have been
identified in EBV-associated malignancies [18]. However,
it remains unclear whether EBV antigens activate patho-
genic Tcregs in NPC. To investigate the existence of
EBV-antigen-specific Tcregs in NPC, we used tetramer
staining to determine the frequency of CD8
+ Tc e l l sa n d
Tcregs from PBMCs and TILs of HLA-A2-positive NPC
patients that were specific for the HLA-A2-restricted
EBV epitopes LMP1 (YLQ) and LMP2 (LLW, GLG).
From the CD8
high cell population, LMP1 (YLQ) and
LMP2 (LLW, GLG) antigen-specific CD8
+ Tc e l l sa n d
CD8
+Foxp3
+ Tregs (Tcregs) were isolated from PBMCs
and TILs of NPC patients (Figure 5A); however, only
antigen-specific CD8
+ T cells but not CD8
+Foxp3
+ Tregs
(Tcregs) were observed in PBMCs of HLA-A2 positive
healthy donors (Additional file 2). Notably, the frequency
of LMP2 epitope LLW antigen-specific CD8
+ T cells was
significantly higher in TILs than in PBMCs, as was the
frequency of YLQ (LMP1) and GLG (LMP2) antigen-spe-
cific Tcregs (Figure 5B) (P < 0.05). This indicates that the
EBV antigen-specific T effector cells and Tcregs can
home to or be induced in NPC tumor tissues.
Discussion
The development and progression of cancer are asso-
ciated strongly with the unique immunosuppressive
characteristics of the tumor microenvironment, regard-
less of the chronic inflammatory response and infiltrat-
ing inflammatory cells that are often produced around
tumor tissue [19-22]. The increase and accumulation of
CD4
+ Tregs in circulating PBMCs and tumor tissues
have been observed in many kinds of malignancy,
including NPC [23-26]. In a recent study, we showed by
double immunohistochemical staining that there was a
CD8
+Foxp3
+ TIL subset in NPC tissues in vivo [17].
In the present study, we showed that the percentage
of CD8
+ Tcregs increased in both circulating PBMCs
and TILs of NPC patients when compared with PBMCs
from healthy individuals (Figure 1, Figure 2A and 2B).
This indicates that the accumulation of Tcregs in tumor
tissue not only results from their recruitment from the
peripheral blood to tumor tissue but also from the
induction of CD8
+ Tcreg precursor cells at the tumor
site. As a consequence, this Tcreg subset should contain
natural Tregs (nTregs) and induced Tregs (iTregs)
together at tumor site. This hypothesis was supported
by the following findings. First, the Tcregs in TILs
expressed CD45RO and CD45RA, which implied that
Tcregs contained both memory and naïve Tcreg cells.
Second, the Tcregs in PBMCs showed high levels of
expression of CCR6, a ligand of chemokine CCL20,
which is usually overexpressed in the NPC tumor
microenvironment and upregulated by the EBV-encoded
LMP1 protein [27,28]. Thus, these cells had migrated to
the tumor tissue. Third, the Tcregs from the TILs
expressed an IFNg
highIL-10
highTGFb
lowIL-2
lowTNFa
lo-
wIL-17
low cytokine secretion phenotype (Tr1-like cyto-
kine profile) (Figure 3). Moreover, we found that the
Tcreg subset also contained some IL-17-producing cells
(approximately 10%) and that the Tcregs from TILs
expressed a significantly higher level of IFNg than those
from PBMCs of patients and controls. These results
indicate that Tcregs in TILs of patients with NPC were
not stable and did secrete some proinflammatory cyto-
kines, such as IL-17 and IFNg.
Our data demonstrate that Tcregs from TILs of NPC
patients can suppress the proliferation of CD4
+ naïve T
cells and CD8
+ effector T cells in vitro. This suppression
was mainly mediated by cell-to-cell contact, and IFNg
did not affect the suppressive function of Tcregs in NPC
(Figure 4). The results are supported by others’ reports
on the mechanism of suppression by Tcregs [29-32],
and they reveal unique functions for Tcregs in NPC
tumor tissue. On one hand, Tcregs facilitate tumor
growth by suppressing activated T cells; on the other
hand, they secrete a large amount of the Th1 cytokine
IFNg, which inhibits tumor cell growth and promotes
the differentiation of Th1 cells.
In recent years, attention has focused on the role of
CD4
+ Th17 cells in solid tumors, but their function
remains largely unclear. Some researchers have sug-
gested that Th17 cells promote tumor growth through
an IL-6/STAT3 pathway, up-regulation of IL-8, and
induction of tumor angiogenesis [33-35]. Others believe
that Th17 cells have an antitumor function and that the
number of Th17 cells is associated with a better out-
come for cancer patients. Additionally, Th17 cells ampli-
fied adoptive CTL immunotherapy in one mouse model
[34,35], and we have identified one CD4
+ Th17 clone
from an NPC patient that could inhibit melanoma
growth in a NOD/SCID mouse model (unpublished
data). However, the role of Th17 cells in NPC remains
poorly understood.
In sum, the present study is the first to investigate the
distribution, generation, and function of Tc17 cells in
NPC. We found that the proportion of Tc17 cells was
reduced significantly in PBMCs when compared to TILs
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Page 7 of 10from NPC patients or to PBMCs from healthy donors
(Figure 2C and 2D). The Tc17 cells in TILs expressed
only CD45RO and not CD45RA (Figure 3A), indicating
that this cell population was derived from memory cells
and migrated from the peripheral blood. In addition, the
high levels of expression of CCR6 in the Tc17 cells
from PBMCs also indicate that these cells were able to
migrate to tumor tissue. Therefore, the proportion of
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Figure 5 Identification of EBV LMP1 and LMP2 epitope-specific CD8
+ T cells and Tcregs in NPC. (A) CD8
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from paired NPC patients or PBMCs from healthy
individuals.
Tc17 cells expressed high levels of IL-17 and TNFa,
intermediate levels of IL-10, and low levels of IL-2.
Similar to Tcregs, Tc17 cells in the TILs but not in
the PBMCs of patients with NPC expressed high levels
of IFNg (Figure 3C). This was consistent with a recent
report of a similar cytokine profile for Tc17 cells in
human liver cancer [36]. Furthermore, other research
groups have shown that Tc17 cells, after polarization
in vitro, can inhibit the growth of B16 tumors in
m o u s em o d e l sb ys e c r e t i n gI F N g in vivo [14,37]. Most
Tc17 cells are derived from CD8
+ T cells that lacked
the expression of T-bet and Eomes; however, the
expression of T-bet and Eomes is important for IFNg
production and for the antitumor function of CD8
+ T
cells, especially in TILs [38]. We also found that in
NPC patients, only Tc17 cells from TILs expressed
high levels of IFNg, which implied that Tc17 from
TILs have a Th1 cell function and might have an anti-
tumor function.
To address whether EBV antigens could induce Tcregs
in NPC, we analyzed Tcregs specific for the EBV HLA-
A2-restricted LMP1 and LMP2 epitopes by tetramer
and Foxp3 staining. We identified CD8
+ T cells and
Tcregs that were specific for the LMP1 epitopes LLW
and YLQ and the LMP2 epitope GLG both in the
PBMCs and TILs from NPC patients (Figure 5). The
percentage of LLW-, YLQ-, and GLG-specific CD8
+ T
cells and Tcregs was increased slightly in TILs as com-
pared to PBMCs, but this increase was only significant
for the LLW epitope antigen-specific CD8
+ T cells and
the YLQ and GLG epitope antigen-specific Tcregs.
These findings demonstrate that EBV epitope-specific
CD8
+ T cells and Tcregs could home to or be induced
in NPC tumor tissues, and some EBV epitope antigens,
specifically YLQ and GLG, induced more antigen-speci-
fic Tcregs in tumor tissues than others. CD4
+ Tregs that
a r es p e c i f i cf o rt h eL A G E 1a n dA R T C 1t u m o ra n t i g e n s
have been identified in melanoma, and EBNA1 P561-573
and P607-619 peptide-specific CD4
+ Tregs have been
identified in PBMCs from healthy donors [39,40]. These
reports indicate that some antigens activate Tregs pre-
ferentially. In sum, the present study is the first to iden-
tify EBV epitopes that can induce antigen-specific CD8
+
Tcregs in PBMCs and TILs of NPC patients. Our results
suggest that when EBV antigen- or peptide-specific CTL
immunotherapy is established for NPC patients, antigen
selection may affect clinical efficacy.
Conclusions
In summary, we determined for the first time that there
were different subsets of CD8
+ T cells, including Tcregs
and Tc17 cells, among the circulating lymphocytes and
TILs of patients with NPC. The results of our study sug-
gest that Tcregs have diverse functions, and they also
indicate a possible antitumor function for Tc17 cells in
NPC tissues. Moreover, we revealed for the first time
the presence of EBV antigen-specific Tcregs in NPC.
Taken together, all these findings provide new insights
into the composition and function of CD8
+ T cells and
will be helpful for the development of T-cell-based
adoptive immunotherapy for NPC.
Additional material
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the proliferation of CD8
+ effector T cells at different ratios.
Additional file 2: Tetramer staining of EBV LMP1 and LMP2 epitope-
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